a tonsillar polyiclcat-2 siv therapeutic vaccine maintains low viremia following antiretroviral therapy cessation扁桃体polyiclcat-2 siv治疗性疫苗抗逆转录病毒治疗停止后维持低病毒血症.pdfVIP

A Tonsillar PolyICLC/AT-2 SIV Therapeutic Vaccine Maintains Low Viremia Following Antiretroviral Therapy Cessation 1 1 1 1 2 Panagiotis Vagenas , Meropi Aravantinou , Vennansha G. Williams , Edith Jasny , Michael Piatak Jr. , 2 3 4 5 1 Jeffrey D. Lifson , Andres M. Salazar , James L. Blanchard , Agegnehu Gettie , Melissa Robbiani * 1 HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, United States of America, 2 AIDS and Cancer Virus Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, Maryland, United States of America, 3 Oncovir Inc., Washington, D. C., United States of America, 4 Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America, 5 Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America Abstract Background: HIV-infected individuals rely on antiretroviral therapy (ART) to control viral replication. Despite abundant demonstrable benefits, the multiple limitations of ART point to the potential advantages of therapeutic vaccination approaches that could provide sustained host control of viral replication after discontinuation of ART. We provide evidence from a non-human primate model that a therapeutic vaccine applied to the tonsils can maintain low viral loads after cessation of ART. Methodology/Principal Findings: Animals received 40 weeks of ART initiated 9 weeks after rectal SIVmac239 infection. During ART, animals were vaccinated (or not) wit